SCHEMBL20135381

SCHEMBL20135381

Cc1cnc(N2CCN(C(=O)c3ccc(C4(c5ccccc5)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
ADAMTS5 Q9UNA0 3/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 5/20 0.43
CRBN Q96SW2 1/20 0.43
AKR1B1 P15121 1/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
CYP2C9 P11712 2/20 0.41
MAPT P10636 2/20 0.41
CACNA1F O60840 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
SCN1A P35498 1/20 0.41
SCN4A P35499 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
CACNA1D Q01668 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135728 0.89 SLC6A7 (0.40) POLBHTTADAMTS5KDM4EALDH1A1
SCHEMBL20134932 0.87 ALDH1A1 (0.42) POLBHTTADAMTS5KDM4EALDH1A1
SCHEMBL20134935 0.87 ALDH1A1 (0.42) POLBHTTADAMTS5KDM4EALDH1A1
SCHEMBL20135056 0.87 CRBN (0.43) POLBHTTADAMTS5ALDH1A1CRBN
SCHEMBL29688915 0.87 CRBN (0.43) POLBHTTADAMTS5ALDH1A1CRBN
SCHEMBL20135259 0.86 ADAMTS5 (0.45) ADAMTS5ALDH1A1MMP2MMP1
SCHEMBL20134972 0.86 ALDH1A1 (0.40) POLBHTTADAMTS5KDM4EALDH1A1
SCHEMBL20134989 0.86 ALDH1A1 (0.40) POLBHTTADAMTS5KDM4EALDH1A1
SCHEMBL20134776 0.84 ADAMTS5 (0.45) ADAMTS5ALDH1A1MMP2MMP1
SCHEMBL20135175 0.84 ALDH1A1 (0.40) POLBHTTADAMTS5KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 POLB 1991/4885HTT 3274/4885ADAMTS5 23/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 POLB 1970/4885HTT 3414/4885ADAMTS5 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.